Libivirumab

Libivirumab (17.1.41) is a human anti-HBV monoclonal antibody. Libivirumab shows neutralization activity with IC50s of 35, 130 ng/mL for HBsAg, HBeAg, respectively[1].

Product Specifications

CAS Number

[569658-79-3]

Product Name Alternative

17.1.41

UNSPSC

12352203

Target

HBV

Type

Inhibitory Antibodies

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/libivirumab.html

Purity

98.27

Solubility

10 mM in DMSO

Smiles

[Libivirumab]

Molecular Weight

(149.04 kDa)

References & Citations

[1]Wang Q, et al. A Combination of Human Broadly Neutralizing Antibodies against Hepatitis B Virus HBsAg with Distinct Epitopes Suppresses Escape Mutations. Cell Host Microbe. 2020 Aug 12;28 (2) :335-349.e6.